Business Context and Reporting Period
Company: The Cooper Companies, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: January 31, 2000
Business Overview: Cooper develops, manufactures, and markets healthcare products through two primary segments: CooperVision (CVI), specializing in contact lenses, and CooperSurgical (CSI), focusing on women's healthcare diagnostic and surgical products.
Key Financial Metrics
| Metric | Q1 2000 | Q1 1999 |
|---|---|---|
| Net Sales | $40.4 million | $35.0 million |
| Gross Profit | $26.6 million (66% margin) | $21.5 million (62% margin) |
| Operating Income | $8.2 million | $5.9 million |
| Net Income | $4.4 million | $3.9 million |
| Diluted EPS (Continuing Ops) | $0.34 | $0.18 |
| Operating Cash Flow | $5.3 million | ($3.4 million) |
| Cash and Equivalents (End of Period) | $2.7 million | $5.8 million |
| Total Debt | $62.6 million | $62.0 million |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 16% year-over-year, driven by 15% growth in CVI and 17% growth in CSI.
- Profitability: Operating income rose 40% to $8.2 million. Gross margin improved to 66% from 62%, attributed to cost reduction projects and manufacturing efficiencies.
- Acquisitions: The company completed two acquisitions in the quarter: BEI Medical Systems products ($10.5 million) and the Leisegang Business ($10 million), totaling $21.6 million in cash outflows for investing activities.
- Cash Flow: Operating cash flow turned positive ($5.3 million) compared to a negative $3.4 million in the prior year, despite significant inventory builds related to acquisitions.
- Debt Refinancing: The company refinanced approximately $18 million of long-term debt, replacing higher-cost debt with funds from a KeyBank line of credit to reduce interest expense.
Guidance, Outlook, and Risks
- Outlook: Management expects cash on hand and operating cash flows to fund operations, dividends, and smaller acquisitions. Additional financing may be required for larger strategic alliances.
- Tax Strategy: A new global corporate structure implemented in late 1999 is expected to lower the effective tax rate to approximately 30% over the next six years.
- Margin Expectations: While CVI margins are expected to improve, CSI margins are projected to average 53% for the full fiscal year due to the integration of lower-margin acquired products.
- Risks: Key risks include foreign currency exchange exposure (hedged for Sterling debt), interest rate fluctuations, integration costs of acquisitions, and potential environmental remediation costs (currently accrued at $400,000 for a groundwater contamination site).
- Accounting Change: A one-time after-tax charge of $432,000 was recorded due to the adoption of SOP 98-5 regarding start-up activities.
Investor Verification Checklist
- Verify the integration progress and revenue contribution of the BEI and Leisegang acquisitions.
- Monitor the actual effective tax rate against the projected 30% long-term target.
- Review the status of the KeyBank line of credit availability ($23.3 million remaining) and future debt repayment schedules.
- Assess the impact of the $4.9 million inventory increase from acquisitions on future working capital needs.
- Confirm the timeline and cost estimates for the environmental remediation at the CVI site.